{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"320"}],"units":"Participants"}],"description":"Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.","groups":[{"description":"Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG000","title":"Treatment A"},{"description":"Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses)\n\nThen\n\nNivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG001","title":"Treatment B"},{"description":"Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle","id":"OG002","title":"Treatment C"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days following last dose (Up to 30 months)","title":"Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation","type":"SECONDARY","unitOfMeasure":"Participants"}